Therapeutic Asset Ratings
436 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
P1/2
CCC
(52)
Binimetinib
Advanced Solid Tumors
Roswell Park Cancer Institute
P2
CCC
(51)
su011248
Advanced Solid Tumors
Canadian Cancer Trials Group
P2
CCC
(51)
RIFALDAZINE
Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
P1
CCC
(51)
Belzutifan
Advanced Solid Tumors
Merck Sharp & Dohme LLC
P2
CCC
(50)
Calderasib
Advanced Solid Tumors
Merck Sharp & Dohme LLC
P2
CCC
(50)
Losartan
Advanced Solid Tumors
Ain Shams University
P2
CCC
(50)
mk-1084
Advanced Solid Tumors
Merck Sharp & Dohme LLC
P2
CCC
(50)
RITONAVIR
Advanced Solid Tumors
DualityBio Inc.
P2
CCC
(50)
Shr-A1811
Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P2
CCC
(50)
Sotorasib
Advanced Solid Tumors
Amgen
P2
CCC
(50)
Spartalizumab
Advanced Solid Tumors
University Hospital, Bordeaux
P2
CCC
(50)
Tucatinib
Advanced Solid Tumors
OnKure, Inc.
P2
CCC
(50)
AZD1775
Advanced Solid Tumors
AstraZeneca
P2
CCC
(48)
Dasatinib
Advanced Solid Tumors
Canadian Cancer Trials Group
P2
CCC
(48)
Lopinavir
Advanced Solid Tumors
DualityBio Inc.
P2
CCC
(48)
Risovalisib
Advanced Solid Tumors
Haihe Biopharma Co., Ltd.
P2
CCC
(48)
Surufatinib
Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
P2
CCC
(48)
VEMURAFENIB
Advanced Solid Tumors
Seoul National University Bundang Hospital
P2
CCC
(48)
2x-121
Advanced Solid Tumors
Allarity Therapeutics
P1/2
CCC
(48)
Anti-EGFR Antibody-drug Conjugate MRG003
Advanced Solid Tumors
Shanghai Miracogen Inc.
P1/2
CCC
(48)
Capecitabine
Advanced Solid Tumors
BOE Technology Group Co., Ltd.
P1/2
CCC
(48)
Darolutamide
Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CCC
(48)
Ivonescimab
Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1/2
CCC
(48)
Shr-A2009
Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CCC
(48)
Showing 51 to 75 of 436 assets
Previous
Page 3 of 18
Next